ARTICLE
9 November 2021

What You Need To Know About The CMS Omnibus COVID-19 Health Care Staff Vaccination Interim Final Rule

SG
Shipman & Goodwin LLP
Contributor
Shipman & Goodwin LLP  logo
Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
The Centers for Medicare & Medicaid Services ("CMS") Omnibus Interim Final Rule ("Final Rule") takes effect November 5, 2021, and with it comes the requirement that Medicare and Medicaid-certified suppliers...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

The Centers for Medicare & Medicaid Services ("CMS") Omnibus Interim Final Rule ("Final Rule") takes effect November 5, 2021, and with it comes the requirement that Medicare and Medicaid-certified suppliers, providers, and their staff become vaccinated for COVID-19. As this new rule becomes a new reality, it is essential that all key stakeholders involved understand: who is impacted by the Final Rule, the Final Rule's vaccination requirements, and how to determine who qualifies as exempt from the Final Rule's vaccination requirement.

Who is Impacted by the Final Rule?

The Final Rule applies to Medicare and Medicaid-certified provider and supplier types that are regulated under the Medicare health and safety standards (collectively "facilities"). Hospitals, Hospice, Community Mental Health Centers, and Comprehensive Outpatient Rehabilitation Facilities are some of the types of facilities that will need to implement policies to ensure their staff complies with the Final Rule. The vaccination requirement applies to all staff, current and new, who provide care, treatment, or other services for the facility and/or its patients. This also includes individuals under contract (or other arrangements) to provide such treatment or services. Offsite staff members who interact with other staff, patients, residents, clients, or PACE program participants in homes, clinics, administrative offices, and beyond what is considered the formal clinical setting are also required to be vaccinated under the Final Rule.

What are the Final Rule's Vaccination Requirements?

The Final Rule requires facilities to establish policies and processes that fulfill the vaccination requirement over two phases. Phase 1 requires that all staff at eligible facilities obtain the first dose of a primary series or a single dose COVID-19 vaccination prior to providing treatment and services for the facility and/or to patients, within 30 days after the Final Rule's publication date, which is November 5, 2021. Phase 1 also requires that facilities have appropriate policies and procedures developed and in place. Phase 2 requires that, within 60 days after publication of the Final Rule, staff at eligible facilities complete the primary vaccination series. Staff who have completed the primary vaccination series by this date are considered to meet these requirements, even if they have not yet completed the two-week waiting period required for full vaccination. Facilities are required to implement processes to ensure they follow nationally recognized infection prevention and control guidelines intended to mitigate transmission of COVID-19 when they have staff that have not completed the two-week waiting period. For purposes of the Final Rule, an individual is fully vaccinated two or more weeks after they have completed a primary vaccination series for COVID-19. Vaccines that count toward the requirement include all vaccines licensed or authorized for emergency use by the Food and Drug Administration, vaccines listed by the World Health Organization for emergency use, and vaccines received during an individual's participation in a clinical trial.

Who is Exempt or Excluded from the Vaccination Requirement under the Final Rule?

Staff with recognized medical conditions for which vaccines are contraindicated may obtain reasonable accommodations under the Americans with Disabilities Act, and staff with religious beliefs, observances, or practices established under Title VII of the Civil Rights Act of 1964 qualify for exemption under the Final Rule. The Final Rule preempts the applicability of any State or local law providing for exemptions to the extent the law provides broader exemptions than Federal law. Facilities have the flexibility and the responsibility to establish their own processes to allow eligible staff to obtain exemptions. Additionally, those excluded from the Final Rule include: individuals who provide services 100 percent remotely and who do not have direct contact with patients or other staff, Religious Nonmedical Health Care Institutions, Organ Procurement Organizations, and Portable X-Ray Suppliers. To ensure compliance, CMS works directly with state survey agencies, who are expected to conduct onsite compliance reviews of requirements.

Although the Final Rule will take immediate effect, stakeholders have 60 days to submit formal comment on this emergency regulation. This comment period officially closes on January 4, 2022, at which point CMS will consider and respond to comments as a part of potential future rulemaking, if needed.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
9 November 2021

What You Need To Know About The CMS Omnibus COVID-19 Health Care Staff Vaccination Interim Final Rule

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Shipman & Goodwin LLP  logo
Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More